Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Leena Helle"'
Autor:
Heikki Joensuu, Vesa Kataja, Minna Tanner, Johan Ahlgren, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Leena Helle, Henrik Lindman, Päivi Auvinen, M. Leinonen, Greger Nilsson, Kenneth Villman, Arja Jukkola-Vuorinen, R. Kokko, Paul Nyandoto, Outi Saarni, Petri Bono
Publikováno v:
Acta Oncologica (Stockholm, Sweden)
Background. Little information is available about survival outcomes of patients with HER2-positive early breast cancer treated with adjuvant capecitabine-containing chemotherapy with or without trastuzumab. Patients and methods. One thousand and five
Autor:
Petri Bono, Marjo Pajunen, Pirkko-Liisa Kellokumpu-Lehtinen, Raija Asola, Paula Poikonen, R. Kokko, Henrik Lindman, Päivi Auvinen, Vesa Kataja, Riikka Huovinen, Minna Tanner, Arja Jukkola-Vuorinen, Paul Nyandoto, M. Leinonen, Heikki Joensuu, Outi Paija, Kenneth Villman, Leena Helle, Johan Ahlgren, Greger Nilsson
Publikováno v:
Journal of Clinical Oncology. 30:11-18
Purpose Capecitabine is an active agent in the treatment of breast cancer. It is not known whether integration of capecitabine into an adjuvant regimen that contains a taxane, an anthracycline, and cyclophosphamide improves outcome in early breast ca
Autor:
Tuomo Alanko, Jorma Isola, Kari Möykkynen, Pirkko-Liisa Kellokumpu-Lehtinen, Petri Bono, Hannu Leinonen, Tapio Utriainen, Päivi Auvinen, T. Salminen, Raija Asola, Leena Helle, Vesa Kataja, Taina Turpeenniemi-Hujanen, Sirkku Jyrkkiö, Marjo Pajunen, Mauri Huusko, Seija Ingalsuo, R. Kokko, Heikki Joensuu, M. Leinonen
Publikováno v:
Journal of Clinical Oncology. 27:5685-5692
Purpose Docetaxel has not been compared with vinorelbine as adjuvant treatment of early breast cancer. Efficacy and long-term safety of a short course of adjuvant trastuzumab administered concomitantly with chemotherapy for human epidermal growth fac
Publikováno v:
Aikuiskasvatus
Espoon terveydenhuolto- ja sosiaalialan oppilaitos järjesti vuoden mittaisen oppisopimuskoulutuksen Espoon päihdehuollon ja lastensuojelun sekä kotihoidon henkilöstölle. Koulutus painottui prosessityöskentelyyn ja kokemukset olivat pääosaltaa
Autor:
Markku Viren, Kari Liippo, Antti Ojala, Leena Helle, Sanna Hinkka, Riikka Huovinen, Matti Jakobsson, Markku Järvinen, Soili Paloheimo, Reijo Salmi, Eija-Riitta Salomaa, Väinämö Nikkanen
Publikováno v:
Acta Oncologica. 33:921-924
The combination of carboplatin and etoposide was evaluated in 61 previously untreated patients with extensive small cell lung cancer. Treatment was given at four-week intervals with 450 mg/m2 of carboplatin intravenously (i.v.) on day 1 and etoposide
Publikováno v:
Journal of Clinical Oncology. 11:467-473
PURPOSE To compare the effect on toxicity and efficacy of the fluorouracil 500 mg/m2, epirubicin 60 mg/m2, and cyclophosphamide 500 mg/m2 (FEC) regimen divided into 4 weekly doses with conventional every-4-week administration in metastatic breast can
Autor:
Arja Jukkola-Vuorinen, Paula Poikonen, Raija Asola, Paul Nyandoto, Lauri Nuortio, Minna Tanner, Kenneth Villman, Marjo Pajunen, Johan Ahlgren, Outi Paija, Pirkko-Liisa Kellokumpu-Lehtinen, Akseli Hemminki, Riikka Huovinen, R. Kokko, Vesa Kataja, Leena Helle, Heikki Joensuu, Petri Bono, Henrik Lindman, Päivi Auvinen, Sirpa-Liisa Lahtela, Greger Nilsson, Kaisa Lehtiö, M. Leinonen
Publikováno v:
The Lancet. Oncology. 10(12)
Standard adjuvant chemotherapy regimens for patients with moderate-to-high-risk early breast cancer typically contain a taxane, an anthracycline, and cyclophosphamide. We aimed to investigate whether integration of capecitabine into such a regimen en
Autor:
M. Leinonen, Mervi Rauhala, Marjo Pajunen, Tapio Utriainen, Raija Asola, Anna-Stina Jääskeläinen, Pirkko-Liisa Kellokumpu-Lehtinen, R. Kokko, Seija Ingalsuo, Maija Tarkkanen, T. Salminen, Akseli Hemminki, Inkeri Elomaa, Tuomo Alanko, Petri Bono, Kaisu Johansson, Vesa Kataja, Martti Flander, Jorma Isola, Leena Helle, Jaana Kaleva-Kerola, Sirkku Jyrkkiö, Taina Turpeenniemi-Hujanen, Heikki Joensuu
Publikováno v:
The New England journal of medicine. 354(8)
We compared docetaxel with vinorelbine for the adjuvant treatment of early breast cancer. Women with tumors that overexpressed HER2/neu were also assigned to receive concomitant treatment with trastuzumab or no such treatment.We randomly assigned 101
Publikováno v:
Acta oncologica (Stockholm, Sweden). 31(2)
Patients (n = 174) with metastatic breast cancer previously untreated with anthracycline cytotoxic agents were randomized into two groups: Group 1 received FEC (5-fluorouracil 500 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 500 mg/m2) once every
Autor:
Soile Numminen, Tenho Hietanen, Leena Helle, Tapani Hakala, Ritva Valavaara, Dace Baltina, Risto T. Johansson
Publikováno v:
Breast Cancer Research and Treatment. 16:S-S
The efficacy of high dose toremifene (240 mg daily) in postmenopausal women with advanced breast cancer is investigated in this ongoing study. At present, 38 patients are fully evaluable. Ten patients have CR (26%), 16 PR (42%) (objective response ra